Sermorelin


GHRH 1-29 analog

A 29-amino-acid synthetic fragment of GHRH (residues 1-29) used for growth hormone deficiency diagnosis and treatment.

Abstract

Sermorelin (GRF 1-29; CAS 86168-78-7; molecular weight 3357.93) is a synthetic peptide consisting of the first 29 amino acids of human growth hormone releasing hormone (GHRH). The 1-29 fragment retains essentially all the GH-stimulating activity of full-length GHRH (44 residues) and was the basis for the FDA approval (under the trade name Geref) for GH deficiency in children. The brand-name product was discontinued in 2008 for commercial reasons; sermorelin is now compounded for clinical use in some jurisdictions and sold as a research chemical. The compound is administered subcutaneously and stimulates pituitary GH release through GHRH receptor activation, distinct from the ghrelin receptor agonism of GHRPs. Combination of sermorelin with a GHRP (ipamorelin, GHRP-2) produces synergistic GH release. Pharmacokinetics: plasma half-life 11 to 12 minutes; subcutaneous bioavailability good.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph